We are live on ! Find out more
MLTX icon

MoonLake Immunotherapeutics
MLTX

43 hedge funds and large institutions have $111M invested in MoonLake Immunotherapeutics in 2021 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 6

0.21% more ownership

Funds ownership: 93.83% → 94.04% (+0.21%)

1% less capital invested

Capital invested by funds: $113M → $111M (-$1.65M)

7% less funds holding

Funds holding: 46 → 43 (-3)

75% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 4

Holders
43
Holders Change
-3
Holders Change %
-6.52%
% of All Funds
0.75%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
8
Reduced
6
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SCA
STALEY CAPITAL ADVISERS
Pennsylvania
+$798K
2
CAC
Cowen and Company
New York
+$623K
3
FC
Finepoint Capital
Massachusetts
+$323K
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$170K
5
MWM
Meridian Wealth Management
Kentucky
+$151K

Top Sellers

Rank Fund Capital Flow
1
LGM
Logos Global Management
California
-$518K
2
MS
Maven Securities
Jersey
-$513K
3
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$330K
4
Wellington Management Group
Wellington Management Group
Massachusetts
-$323K
5
SCM
Silverarc Capital Management
Massachusetts
-$101K
Name Holding Trade Value Shares
Change 		Change in
Stake
PMAM
26
Picton Mahoney Asset Management
Ontario, Canada
$692K – – –
CAC
27
Cowen and Company
New York
$622K +$623K +62,475 New
MF
28
Magnetar Financial
Illinois
$608K +$3.52K +353 +0.6%
GCL
29
Glazer Capital LLC
New York
$577K +$6.91K +692 +1%
Millennium Management
30
Millennium Management
New York
$555K – – –
PCM
31
Prelude Capital Management
New York
$498K – – –
TD Asset Management
32
TD Asset Management
Ontario, Canada
$442K – – –
MWM
33
Meridian Wealth Management
Kentucky
$415K +$151K +15,094 +56%
D.E. Shaw & Co
34
D.E. Shaw & Co
New York
$395K +$170K +17,040 +74%
EAM
35
Exos Asset Management
New York
$250K – – –
RCM
36
Radcliffe Capital Management
Pennsylvania
$248K – – –
ECM
37
ExodusPoint Capital Management
New York
$247K – – –
Nomura Holdings
38
Nomura Holdings
Japan
$226K -$22.1K -2,216 -9%
CC
39
Caxton Corporation
New Jersey
$158K – – –
Janus Henderson Group
40
Janus Henderson Group
United Kingdom
$150K -$330K -33,095 -69%
HF
41
HRT Financial
New York
$140K -$70 -7 -0%
Morgan Stanley
42
Morgan Stanley
New York
$132K +$75.3K +7,549 +128%
TRCT
43
Tower Research Capital (TRC)
New York
$1K +$998 +100 +588%
LGM
44
Logos Global Management
California
– -$518K -50,000 Closed
MS
45
Maven Securities
Jersey
– -$513K -50,000 Closed
PAM
46
Panagora Asset Management
Massachusetts
– -$74K -7,212 Closed
UBS Group
47
UBS Group
Switzerland
– -$4K -374 Closed
1
2

MLTX Hedge Fund Activity: Q3 2021 in Review

43 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in MoonLake Immunotherapeutics (MLTX) for Q3 2021, worth a combined $111M — down 1.5% from $113M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of MLTX and 1 opened new positions — a net loss of 3 holders — while 6 trimmed existing stakes and 8 added.

The largest buyer was STALEY CAPITAL ADVISERS, adding an estimated $798K. The largest seller was Logos Global Management, exiting entirely with an estimated $518K sold.

  • 43 institutional investors held MoonLake Immunotherapeutics (MLTX) as of Q3 2021, down from 46 in Q2 2021.
  • Funds reported $111M of MoonLake Immunotherapeutics stock for Q3 2021, down 1.5% quarter-over-quarter.
  • 1 fund opened new MoonLake Immunotherapeutics positions in Q3 2021 and 4 closed out, a net change of -3 holders.
  • The largest MoonLake Immunotherapeutics buyer in Q3 2021 was STALEY CAPITAL ADVISERS, an estimated $798K added.
  • The largest MoonLake Immunotherapeutics seller in Q3 2021 was Logos Global Management, an estimated $518K sold.

Based on aggregated 13F filings for Q3 2021.